Quest Diagnostics' (DGX) in recent times has continually outperformed the
S&P 500 and seen its
stock value surge by 38% in the past year alone. The company's
financial results from
Q4 and full year 2024 were promising, with updated
guidance for 2025 also released. A deciding factor in its growth can be attributed to the company's
partnership with Google Cloud to leverage AI for
healthcare data transformation. This initiative has pioneered a revolution in
lab testing with the adoption of
Google Cloud AI. Significant transactions include the
acquisition of the Outreach Lab Services business from University Hospitals and LifeLabs, as well as the
acquisition of select laboratory assets from Fresenius Medical Care and Allina Health. Furthermore, the company has announced an increase in its
quarterly dividend to $0.80 per share. Other highlights include
strategic collaborations, such as the one with Sentara Health Plans, aimed to extend lab access. Also noteworthy is Quest Diagnostics' position on the
Fortune's Elite list and its recognition as a 'Best Place to Work for Disability Inclusion' for the seventh consecutive year.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 29 Mar 2025 12:37:40 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 1
